Neumora Therapeutics, INC Form 4 insider transactions

Director and major shareholder Kristina Burow received 80,000 stock options with an exercise price of $1.86 as part of her compensation.

Director Matthew K. Fust was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of standard equity compensation.

Neumora Therapeutics director David Piacquad was granted 80,000 stock options as part of standard equity compensation.

Director Alaa Halawa was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Maykin Ho was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of a standard equity compensation plan.

Neumora Therapeutics' Chief Operating and Development Officer, Daljit Singh Aurora, sold 6,165 shares of common stock to cover tax withholding obligations.

Neumora Therapeutics President Joshua Pinto sold 5,967 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Neumora Therapeutics CEO Paul L. Berns sold 9,819 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Neumora Therapeutics CFO Michael Lee Milligan sold 1,436 shares of common stock to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Neumora Therapeutics' Chief Financial Officer, Michael Lee Milligan, was granted 350,000 stock options with a $2.33 exercise price, vesting over four years.

Neumora Therapeutics' Chief Operating and Development Officer, Daljit Singh Aurora, was granted 750,000 stock options with a $2.33 exercise price.

Neumora Therapeutics' Chief Legal and Administrative Officer, Jason Duncan, was granted 750,000 stock options with an exercise price of $2.33, vesting over four years.

Neumora Therapeutics President Joshua Pinto was granted 1.2 million stock options with a $2.33 exercise price, vesting over four years.

Neumora Therapeutics' CEO and Chairman, Paul L. Berns, was granted 1,650,000 stock options with a $2.33 exercise price, vesting over four years.

Neumora Therapeutics' Chief Operating and Development Officer, Daljit Singh Aurora, sold 114,703 shares of common stock for $2.6767 per share under a pre-arranged 10b5-1 trading plan.

Kristina Burow, a Director and 10% owner of Neumora Therapeutics, acquired nearly 2 million shares of common stock through a pre-planned ARCH Venture Fund transaction.

ARCH Venture Partners XII, LLC and affiliated entities plan to acquire 1.9 million shares of Neumora Therapeutics common stock for $2.61 per share, increasing their beneficial ownership.

ARCH Venture Partners X, LLC and affiliated funds reported a pre-planned acquisition of 1,915,700 shares of Neumora Therapeutics, Inc. common stock by ARCH Venture Fund XII, L.P. at $2.61 per share, effective October 27, 2025.

Neumora Therapeutics, Inc. shareholders approved the repricing of stock options held by Chief Financial Officer Michael Lee Milligan, significantly lowering the exercise price from $1.69 to $0.72 per share.

Neumora Therapeutics, Inc. has repriced stock options for Chief Legal and Administrative Officer Jason Duncan and other key personnel, significantly reducing the exercise price to $0.72 per share from $1.69, following stockholder approval.

Neumora Therapeutics, Inc. director Matthew K. Fust's stock options were repriced to an exercise price of $0.72 per share after shareholder approval on May 28, 2025, contingent on continued service.

Neumora Therapeutics, Inc. director Kristina Burow has had existing stock options repriced to a lower exercise price and received a new option grant, following approval by the company's stockholders on May 28, 2025.

Neumora Therapeutics, Inc. has repriced stock options for Chief Operating and Development Officer Daljit Singh Aurora, reducing the exercise price from $1.69 to $0.72 per share, following stockholder approval on May 28, 2025.

Neumora Therapeutics, Inc. announced that its stockholders approved the repricing of stock options for Director David Piacquad and other insiders, significantly lowering the exercise price to $0.72 per share.

Neumora Therapeutics, Inc. (NMRA) has repriced stock options for its CEO and Chairman, Paul L. Berns, and other key personnel, significantly lowering the exercise price from $1.69 to $0.72 per share.

Neumora Therapeutics, Inc. (NMRA) announced that its stockholders approved the repricing of stock options for Director Maykin Ho and other key personnel, significantly lowering the exercise price to $0.72 per share.

A director at Neumora Therapeutics, Inc. has received repriced stock options and a new option grant, approved by shareholders, adjusting exercise prices to incentivize future performance.

Neumora Therapeutics, Inc. (NMRA) has repriced stock options for its President, Joshua Pinto, significantly lowering the exercise price from $1.69 to $0.72 per share, following stockholder approval on May 28, 2025.

Joshua Pinto, President of Neumora Therapeutics, Inc., transferred 13,202 shares of common stock to a family limited liability company, maintaining investment control.

Paul L. Berns, a director and officer of Neumora Therapeutics, sold shares of common stock on February 18, 2025, to cover withholding tax obligations related to vesting restricted stock units.